0000899243-22-034368.txt : 20221027
0000899243-22-034368.hdr.sgml : 20221027
20221027212303
ACCESSION NUMBER: 0000899243-22-034368
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220913
FILED AS OF DATE: 20221027
DATE AS OF CHANGE: 20221027
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rolph Timothy
CENTRAL INDEX KEY: 0001779479
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 221338815
MAIL ADDRESS:
STREET 1: C/O AKERO THERAPEUTICS, INC.
STREET 2: 170 HARBOR WAY, 3RD FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2022-09-13
2022-09-15
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001779479
Rolph Timothy
C/O AKERO THERAPEUTICS, INC.
601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Scientific Officer
Common Stock
2022-09-13
4
M
0
10000
6.36
A
256337
D
Common Stock
2022-09-13
4
S
0
22500
29.18
D
233837
D
Stock Option (Right to Buy)
6.36
2022-09-13
4
M
0
10000
0.00
D
2029-01-15
Common Stock
10000
62756
D
On September 15, 2022, the reporting person filed a Form 4 which inadvertently omitted the exercise of 10,000 options by the reporting person. The shares of Common Stock underlying those options were subsequently sold pursuant to a Rule 10b5-1 trading plan as reported in the original Form 4. This amendment to the original Form 4 is being filed solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock.
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2021, previously adopted by the reporting person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
This option shall vest and become exercisable in 48 equal monthly installments, commencing on January 1, 2019.
/s/ Jonathan Young, Attorney-in-Fact
2022-10-27